Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization

NCT05125874 | Unknown

• 1 other identifier: ICV-V-01-Booster
• Study Type: interventional
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

Conditions

COVID-19 Pandemic

Keywords

V-01 Booster

Outcome Measures

Primary Outcomes (3)

• Seroconvension of SARS-CoV-2 neutralizing antibodies

  The seroconvension of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization

  14 days and 28 days after booster immunization

• GMT of SARS-CoV-2 neutralizing antibodies

  The GMT of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization

  14 days and 28 days after booster immunization

• GMI of SARS-CoV-2 neutralizing antibodies

  The GMI of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization

  14 days and 28 days after booster immunization

Secondary Outcomes (8)

• GMT of SARS-CoV-2 (wild type) neutralizing antibodies

  Before and on day 7 after booster immunization

• Seroconvension of SARS-CoV-2 (wild type) neutralizing antibodies

  On day 7 after booster immunization

• GMI of SARS-CoV-2 (wild type) neutralizing antibodies

  On day 7 after booster immunization

• GMT of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies

  Before and on day 7, day 14, day 28 after booster immunization

• Seroconvension of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies

  On day 7, day 14, day 28 after booster immunization

Study Arms (1)

V-01 COVID-19 Vaccine

EXPERIMENTAL

One dose administrated by intramuscular injection

Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine

Interventions

Recombinant SARS-CoV-2 Fusion Protein Vaccine BIOLOGICAL

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Also known as: V-01

V-01 COVID-19 Vaccine

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants aged 18 years and older who have completed the second dose of 2-dose regimen of inactive vaccination (Vero cell) against SARS-CoV-2 in the past 3-6 months;
• Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
• In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
• Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.

You may not qualify if:

• Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR.
• History of previous COVID-19 infection.
• Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.
• History of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of V-01.
• People who currently suffer from the following diseases:
• Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
• Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
• Patients with congenital or acquired angioedema/neuroedema;
• A history of congenital or acquired immunodeficiency or autoimmune disease (except for mild psoriasis, controllable autoimmune thyroid disease, vitiligo, or stable celiac disease that does not require immunosuppressive or immunomodulatory therapy); no spleen , or history of spleen surgery, history of trauma, or treatment with immunomodulators within 6 months, such as: glucocorticoid with the dose causing immunosuppressive (dose reference: equivalent to prednisone 20mg/day, more than one week); or monoclonal antibody ; or thymosin; or interferon, etc.; but local medication (such as ointment, eye drops, inhalation or nasal spray) is allowed.
• Patients with active tuberculosis, viral hepatitis, human immunodeficiency virus or syphilis infection.
• Patients with acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases: history of chronic respiratory diseases (including moderate to severe asthma, COPD, pulmonary fibrosis), hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmHg) And/or diastolic blood pressure ≥100mmHg), history of severe cardiovascular disease (including heart failure, coronary artery disease, cardiomyopathy), history of chronic kidney disease, history of cancer (except for basal cell carcinoma), diabetes (unsatisfied blood sugar control or diabetes related serious complications).
• Received attenuated live vaccine within 28 days before the vaccination or any subunit vaccines and inactivated vaccines within 14 days before the vaccination.
• Injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; or with the plan to use such product within 6 month after immunization.
• Pregnant (including positive urine pregnancy test for women of childbearing age) or breastfeeding women. Or women or their partners who have a pregnancy plan within 3 months after the trial vaccination.
• Have participated in or are participating in other COVID-19 related clinical trials, or are participating in other drug clinical trials;

Sponsors & Collaborators

• Livzon Pharmaceutical Group Inc.: lead

Study Sites (1)

Zhuhai Peoples' Hospital Medical Group

Zhuhai, Guangdong, 519000, China

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Ligong Lu, Dr.

  Zhuhai People's Hospital Medical Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 9, 2021
• First Posted: November 18, 2021
• Study Start: September 30, 2021
• Primary Completion: August 30, 2023
• Study Completion: September 30, 2023
• Last Updated: November 18, 2021

Record last verified: 2021-11

Locations

CN (1)